18 results about "Motor dysfunction" patented technology

The application relates to the technical field of new uses of medicines, and particularly discloses application of an N-phenylpiperazine derivative in preparation of a medicine for treating Parkinson's disease, wherein the N-phenylpiperazine derivative is HS. + The N-phenylpiperazine derivative HS provided by the application can significantly improve the survival rate of SH-SY5Y cells induced by MPP + , shows a dose-dependent neuroprotective effect, can effectively improve the motor dysfunction of a model animal, increase the open field movement distance, prolong the time of staying on a rotating rod, and provides a new selection for developing an anti-Parkinson's disease treatment medicine with a neuroprotective effect.

The present invention relates to the technical field of neural stimulation, and specifically relates to a non-invasive spinal cord stimulator for upper limb motor function recovery, comprising a cervical spinal cord pulse control unit, an electrode connection unit, a motion monitoring unit, a wireless communication unit, a speech unit, a paradigm decision unit, an electrode array unit, and an artificial intelligence unit. In the present invention, the non-invasive spinal cord stimulator acts on a specific cervical spinal cord segment by means of non-invasive cervical spinal cord stimulation technology, inducing the reconstruction of a spinal cord neural network, strengthening synaptic connection, treating upper limb motor dysfunction of paralyzed individuals, and achieving upper limb motor function recovery.

Methods and compositions for manipulating metabolism in astrocytes to improve astrocytic and neuronal function, as well as individual pathology hallmarks and symptoms during the development of neurodegeneration by increasing PPARα expression and activity specifically in astrocytes within the central nervous system to treat a variety of neurodegenerative conditions including but not limited to conditions involving neuronal lipid dysregulation, oxidative damage, accumulation of β-amyloid or other protein aggregates, dementia, and motor dysfunction. Also provided are methods of treating peripheral metabolic dysfunction associated with neurodegenerative conditions.

The application discloses a gait evaluation method and device, electronic equipment and storage medium, and relates to the technical field of gait analysis. In the application, gait data of a person with motor dysfunction in adjacent multiple walking cycles is obtained; the gait data comprises a gait phase parameter set and a posture angle parameter set of the person with motor dysfunction; from the gait phase parameter set and the posture angle parameter set included in the gait data, a gait phase parameter subset and a posture angle parameter subset corresponding to each of multiple gait evaluation dimensions are determined; based on the gait phase parameter subset and the posture angle parameter subset corresponding to each of the multiple gait evaluation dimensions, gait evaluation of the person with motor dysfunction is performed in the multiple gait evaluation dimensions to obtain multiple gait evaluation values; and based on the multiple gait evaluation values and gait evaluation weight values corresponding to the multiple gait evaluation values respectively, a comprehensive gait evaluation value of the person with motor dysfunction is determined. In this way, the gait data of the person with motor dysfunction is comprehensively quantified, and the accuracy of gait evaluation is improved.

This utility model relates to a leg exercise device for neurological rehabilitation, belonging to the technical field of leg exercise devices. It includes a seat assembly and two symmetrically arranged leg training mechanisms. Each training mechanism includes a control component and a training component. The training component includes a hip joint mechanism hinged to the seat assembly, a large arm guard hinged to the hip joint mechanism, and a forearm guard hinged to the distal end of the large arm guard. Servo direct drive mechanisms are provided at both the hip and knee joint hinges. A magnetorheological fluid rotary damper is coaxially arranged at the knee joint hinge. A travel limit sensor and a torque sensor for muscle tension detection are provided at the hinge. The servo direct drive mechanism, the magnetorheological fluid rotary damper, and the torque sensor are all electrically connected to the control component. It features a built-in passive, assisted active, and resistance-enhanced three-level training mode and bilateral independent operation. This utility model, through its three-level training mode, can cover the training of patients with lower limb motor dysfunction in neurology, lowering the rehabilitation threshold for patients.

The application discloses application of bupropion hydrochloride tablets (75mg) in preparation of a medicine for treating stroke, and belongs to the technical field of new purposes of medicines. The core verifies the efficacy and safety of the medicine of the specification through systematic animal tests, aims at the problems of post-stroke neural function defect, motor dysfunction and insufficient neural plasticity, adopts a line plug method to prepare a rat focal cerebral ischemia (MCAO) model, sets multiple control tests, and explores the dosing effect of an equivalent dose of the bupropion hydrochloride tablets (75mg). The test results show that the medicine can significantly reduce the neural function defect score of the model animals, improve the motor coordination ability and the limb usage rate, increase the content of brain-derived neurotrophic factor (BDNF) in the brain, promote the repair of neural plasticity, and is safer than a high-dose scheme and has no obvious adverse reactions. Through complete animal test data, the application proves the effectiveness and safety of the bupropion hydrochloride tablets (75mg) in treating stroke, provides solid test basis for clinical conversion and application of the bupropion hydrochloride tablets (75mg), and has important medical application value.

Provided is a closed-loop neuromodulation system involving coordinated intervention of the brain, the spinal cord, and the lumbosacral region, which comprises a deep brain stimulation unit (401), a deep brain field potential sensing unit (402), a spinal cord stimulation unit (501), an evoked potential sensing unit (502), a control decision-making unit (10), a deep brain electrode (403), a spinal cord electrode (503), a lumbosacral electrode (602), a docking lead (601), a radio frequency transmission unit (20), and a wireless charging and power management unit (30). By constructing an application strategy for coordinated regulation of the brain, the spinal cord, and the lumbosacral region, only one neurostimulator needs to be implanted. It can be used alone for brain diseases or spinal cord-related diseases, and can also be used for coordinated stimulation for motor function reconstruction and recovery in paralyzed patients and patients with motor dysfunction, as well as for the treatment of urinary system complications. The whole system is modular in application, can be selectively used according to disease conditions, and has a wider application range.

The application belongs to the field of thrombus-related circulatory disorder disease treatment, and provides application of a Rev-erb alpha agonist in preparation of an anti-platelet aggregation and thrombus-related circulatory disorder medicine. The application finds a new pharmacological effect of the Rev-erb alpha agonist, which can significantly inhibit platelet activation and aggregation, block arterial thrombosis in the whole circulatory system, and increase the level of ischemic area cortical blood supply within 0.5 to 1 hours after stroke. The blood supply increasing approach is recanalization of the infarction area circulatory system, rather than compensation by collateral supply arteries, finally significantly improving motor dysfunction caused by cerebral infarction; and the application provides a new idea and a new drug selection for clinical treatment of coronary heart disease, limb arterial thrombosis, visceral thrombosis, ischemic stroke, disseminated intravascular coagulation, peripheral thrombosis and the like.

The application provides a method for treating autism spectrum disorder (ASD) based on terahertz wave intervention and application thereof. The method comprises the following steps: dividing mice into four groups according to groups, each group having two types of mice; testing baseline behaviors of anxiety, motor ability and social ability of each group of mice; after a set time of completion of baseline behavior testing, using a THz-VNS device to intervene in each group of mice by THz-VNS; after the mice wake up, behavior testing is performed after a set time of completion of THz-VNS intervention; and statistically analyzing the behavior testing results to obtain the intervention results of THz-VNS intervention on ASD. By comparing the behavior testing results of wild type and ASD model mice before and after intervention, it is proved that the intervention method can improve the anxiety abnormality, motor dysfunction and social dysfunction of ASD model mice, which indicates that the intervention method can be used for the treatment of ASD. Meanwhile, the intervention method has a wide influence on the nervous system function, so the intervention is not limited to the treatment of ASD, but can also be extended to various nervous system diseases.

This invention relates to the field of pharmaceutical technology for treating motor dysfunction in Parkinson's disease, and particularly to a traditional Chinese medicine preparation for treating motor dysfunction in Parkinson's disease. The formula consists of Cimicifuga rhizome, processed turtle shell, Angelica sinensis, raw licorice root, ginger-processed Pinellia ternata, Gastrodia elata, and scorpion. This invention uses a traditional Chinese medicine formula to treat motor dysfunction in Parkinson's disease. The medicinal materials comply with national regulations for the management of traditional Chinese medicine materials and have undergone clinical testing. The formula is rationally formulated with high synergistic effects and long-lasting and stable efficacy. Based on the principles of traditional Chinese medicine syndrome differentiation and treatment, this formula addresses the deficiency of both liver and kidney, and the insufficiency of qi and blood, with tremor and paralysis attributed to internal liver wind. It significantly improves motor dysfunction and tremor symptoms in Parkinson's disease. This preparation is highly effective, safe, reliable, and has few side effects. It can also significantly reduce the expression levels of tyrosine hydroxylase in the substantia nigra and striatum. This preparation represents a new approach to treating motor dysfunction in Parkinson's disease and has broad prospects in the field of treating this condition.

The application belongs to the technical field of biological medicine, and discloses application of PPIA in preparation of a medicine for preventing or treating Parkinson's disease, wherein an amino acid sequence of the PPIA is shown as SEQ ID NO. 5. The application proves for the first time that PPIA expression is significantly up-regulated in Parkinson's disease cells and mouse models; by inhibiting the expression or activity of PPIA, the damage of dopaminergic neurons in the Parkinson's disease model can be significantly reduced, and the motor dysfunction of the model mice can be improved. Meanwhile, the application also finds for the first time that paederoside can significantly inhibit the expression of PPIA, and is a new specific inhibitor of PPIA. The application determines that PPIA is a brand-new drug target for preventing and treating Parkinson's disease, and can be used for screening and discovering medicines for preventing and treating Parkinson's disease, and can inhibit the death of dopaminergic neurons by inhibiting the expression of PPIA, thereby providing a new direction and theoretical basis for the research and development of medicines for preventing or treating Parkinson's disease and clinical treatment.

The present application relates to a kind of traditional Chinese medicine composition for treating nerve root type cervical spondylosis, preparation and preparation method thereof.The traditional Chinese medicine composition includes peach kernel, safflower, chuanqiong, angelica, wind-preventing plant, catmint, turmeric, qianghuo, baizhi, vitex, danshen, suomu, frankincense, myrrh and kudzu root.The traditional Chinese medicine composition can be made into various kinds of pharmaceutical preparations according to conventional process.The composition and its preparation can regulate qi and blood, dredge meridians, improve physiological curvature of cervical vertebra, reduce nerve root compression, relieve neck and shoulder pain, promote local blood circulation, significantly improve upper limb numbness and motor dysfunction, have significant curative effect and long-lasting effect, have the advantages of simple, safe and economical, etc., can be used as an important supplementary means for treating nerve root type cervical spondylosis, help to reduce the treatment burden of patients, meet their diversified treatment needs.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN3 RNA in a cell or animal, and in certain embodiments reducing the amount of ATXN3 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include motor dysfunction, aggregation formation, and neuron death. Such neurodegenerative diseases include spinocerebellar ataxia type 3(SCA3).

This invention provides a plant-derived bioactive polypeptide and its use in the prevention or treatment of Parkinson's syndrome, belonging to the field of polypeptide bioengineering technology. The amino acid sequence of the bioactive polypeptide is MKGASSIMYALG, and it is prepared from Fuding white tea raw materials through a directed two-step enzymatic hydrolysis process. This polypeptide can significantly alleviate 6-OHDA-induced damage to dopaminergic neurons in BZ555 nematodes and significantly improve motor dysfunction in Parkinson's syndrome model animals. Simultaneously, it can downregulate the expression levels of pro-inflammatory factors such as IL-1β and IL-18 in the serum of model mice, upregulate dopamine content in the substantia nigra region of brain tissue in model rats, and reduce monoamine oxidase B activity. These results indicate that the Fuding white tea-derived bioactive polypeptide of this invention has definite preventive and therapeutic effects on Parkinson's syndrome, and has significant development value and broad application prospects in the pharmaceutical field.

The application discloses a kind of stimulating electrodes for nerve motor function recovery after spinal cord injury, including catheter, stimulating electrode piece and guide wire;The cross section of the catheter is rectangular, two stimulating electrode pieces are a group, and a plurality of stimulating electrode pieces are arranged at fixed distance on the catheter, and each group of stimulating electrode pieces is arranged on the both sides outside the catheter respectively, and each stimulating electrode piece is connected with the outside by connecting the corresponding guide wire arranged in the catheter respectively;Soft barb is arranged above the same side of each stimulating electrode piece in the catheter.The stimulating electrode for nerve motor function recovery after spinal cord injury of the utility model is suitable for the electrical stimulation treatment of upper and lower limb motor dysfunction after spinal cord injury, can be applied to patients of different ages, and can effectively continuously stimulate the specific nerve root motor bundle of patient, with good curative effect.

1. Name of the product in this design: Vibration Rehabilitation Training Bed. 2. Purpose of this design: To improve muscle function, balance, and coordination in patients with motor dysfunction. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The application discloses a polypeptide UPCP and application thereof in preparation of anti-aging products. The polypeptide UPCP provided by the application has an amino acid sequence of sequence 4 in the sequence list. The polypeptide is applied in preparation of products with any one of the following functions: 1) treating children's premature aging; 2) delaying physiological aging of mammals or cells thereof; 3) improving premature aging of mammals; the improvement of premature aging of mammals is embodied in delaying premature aging of mammals; 4) improving body weight of premature aging animals; the improvement of body weight of premature aging animals is embodied in increasing body weight of premature aging animals; 5) relieving motor dysfunction of premature aging animals; 6) prolonging survival period of premature aging animals, etc. The application develops a specific peptide (UPCP) which can inhibit HGPS cell aging, improve aging characteristics of HGPS premature aging mice and prolong survival period, and provides a new strategy for treatment of HGPS.